drugset

drugset / Trial / NCT02843204

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

NCT02843204 ↗

Phase 1/2 Completed 110 enrolled Fuda Cancer Hospital, Guangzhou Shenzhen Hank Bioengineering Institute · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is the safety and efficacy of anti-PD-1 plus NK immunotherapy to multiple solid tumors.

Timeline

Start: 2016-07-01
Primary completion: 2017-07-01
Completion: 2019-07-01

Publications

Lin M, Luo H, Liang S, Chen J, Liu A, Niu L, Jiang Y. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest. 2020 May 1;130(5):2560-2569. doi: 10.1172/JCI132712.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NK immunotherapy	Cell therapy	1e+10 cells	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	10 mg/kg	Intravenous

Indications